Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
General5 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News22 hours agoBrisbane’s original 1979 electric trains take one last journey
-
General21 hours agoParis opens River Seine for public swimming for first time since 1923
-
General19 hours agoDr Daniel Hunt, Michael Long and Christine Anu celebrated at 50th NAIDOC Week Awards